Phio's PH-762 Shows Strong Responses, Cash Extended to Q2 2026 but Dilution Risks Loom

Phio Pharmaceuticals Corp. (NASDAQ: PHIO)

Financials below are presented as in the company filing (amounts in thousands, unaudited).

Quick take - what's happening inside: Phio is a clinical-stage immuno-oncology company focused on INTASYL siRNA candidates (PH-762 and PH-894). The company advanced its PH-762 Phase 1b (15 patients treated to date; SMC cleared escalation to cohort 5) and continues to prioritize that program. Management has raised capital through multiple registered-direct/private placements and warrant exercises, materially increasing cash on hand but also increasing share count and outstanding warrants. The company still reports recurring operating losses and says there is substantial doubt about its ability to continue as a going concern without further financing.

Key points & statistics
- Cash and cash equivalents: $10,775 (June 30, 2025) vs $5,382 (Dec 31, 2024).
- Total assets: $11,301 (June 30, 2025) vs $5,738 (Dec 31, 2024).
- Total current liabilities: $1,206 (June 30, 2025).
- Total stockholders' equity: $10,095 (June 30, 2025) vs $4,723 (Dec 31, 2024).
- Accumulated deficit: (150,291) (June 30, 2025) vs (146,356) (Dec 31, 2024).
- Common shares issued & outstanding: 4,798,154 (June 30, 2025); 5,726,750 shares outstanding as of Aug 12, 2025 (post-period).
- Weighted average shares outstanding (basic and diluted) - three months ended June 30, 2025: 4,794,857 vs 510,188 (2024).
- Warrants outstanding: 6,601,118 (June 30, 2025).
- Research & development expense (Q2): $1,074 (Q2 2025) vs $866 (Q2 2024) - +24%.
- General & administrative expense (Q2): $1,235 (Q2 2025) vs $1,048 (Q2 2024) - +18%.
- Total operating expenses (Q2): $2,309 (Q2 2025) vs $1,914 (Q2 2024).
- Operating loss (Q2): (2,309).
- Net loss (Q2): (2,166) vs (1,846) (Q2 2024) - worsened by 320.
- Net loss (six months): (3,935) (2025) vs (4,000) (2024) - improved by 65.
- Net loss per share, basic and diluted (Q2): (0.45) (2025) vs (3.62) (2024) - impacted by large increase in weighted average shares.
- Cash flow: Net cash used in operating activities (six months): (3,815). Net cash provided by financing activities (six months): 9,213. Net increase in cash for period: 5,393.
- Company statement: cash runway expected into Q2 2026 (subject to variability); company discloses substantial doubt about going concern without additional funding.
- Clinical progress: PH-762 Phase 1b - 15 patients treated; among 13 cSCC patients at Day 36: 5 pathologic complete responses (100% tumor clearance), 1 near complete (>90%), 1 partial (>50%); no dose-limiting toxicities reported; cohort 5 enrolling.

Positive aspects of the income statement / position
- Cash balance more than doubled year-to-date to $10,775, driven by financings and warrant exercises (net proceeds from January 2025 financings ~ $6.7M reported).
- Six-month net loss improved slightly year-over-year: (3,935) vs (4,000) - small progress on YTD loss trend.
- Operating discipline: operating expenses YTD relatively flat (4,181 vs 4,123) despite clinical advancement; management reduced headcount and facility costs in prior periods and redirected spending to the PH-762 program.
- Strong clinical signals in PH-762 (multiple complete responses in treated cSCC patients and no DLTs) - a material non-financial positive that supports program value.

Negative aspects of the income statement / position
- Recurring operating losses continue: Q2 net loss widened to (2,166) from (1,846) - quarter-over-quarter expense pressure from higher R&D (patient enrollment) and higher G&A (salaries for new hires).
- Negative operating cash flow remains: net cash used in operating activities (six months) (3,815).
- Accumulated deficit worsened to (150,291).
- Heavy potential dilution risk: weighted average shares jumped to ~4.8M from ~0.51M (impacting per-share metrics) and warrants outstanding are 6.6M - significant overhang.
- Company discloses substantial doubt about going concern and will need additional capital beyond the documented runway (into Q2 2026) to sustain operations and clinical programs.
- Termination of AgonOx collaboration removes potential milestone/royalty upside (but also removes future funding obligations).

Bottom line: Phio has made clear clinical progress on PH-762 and materially improved its cash position via financings, extending runway into 2026. However, the business still generates operating losses, relies on continued equity financings, faces meaningful dilution risk from warrants and newly issued shares, and explicitly discloses substantial doubt about its ability to continue without new capital. Key near-term catalysts to watch: PH-762 cohort 5 enrollment/results, warrant exercises/financings, and any strategic partnerships or additional registered offerings.

Sources: Phio Pharmaceuticals Corp. Form 10-Q for quarter ended June 30, 2025 (filed Aug 14, 2025).